<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Res Treat</journal-id><journal-id journal-id-type="publisher-id">ART</journal-id><journal-title-group><journal-title>AIDS Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">2090-1240</issn><issn pub-type="epub">2090-1259</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23401755</article-id><article-id pub-id-type="pmc">3562599</article-id><article-id pub-id-type="doi">10.1155/2013/580974</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of a Phone Call Intervention to Promote Adherence to Antiretroviral Therapy and Quality of Life of HIV/AIDS Patients in Baoshan, China: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Dongsheng</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sangthong</surname><given-names>Rassamee</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McNeil</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chongsuvivatwong</surname><given-names>Virasakdi</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Weibin</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xuemei</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Preventing and Controlling HIV/AIDS, Baoshan Prefecture Center for Disease Control and Prevention, Baoshan, Yunnan 678000, China</aff><aff id="I2"><sup>2</sup>Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai 90110, Thailand</aff><aff id="I3"><sup>3</sup>Baoshan Prefecture AIDS Working Committee Office, Baoshan Prefecture Health Bureau, Baoshan, Yunnan 678000, China</aff><author-notes><corresp id="cor1">*Dongsheng Huang: <email>hudosh_007@126.com</email></corresp><fn fn-type="other"><p>Academic Editor: P. K. Nicholas</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>17</day><month>1</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>580974</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Dongsheng Huang et al.</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Background</italic>. Suboptimal adherence to antiretroviral therapy (ART) is still pervasive. The effect of using a mobile phone call intervention to improve patient adherence is currently not known. <italic>Objective</italic>. This study aims to investigate the effects of a phone call intervention on adherence to ART and quality of life (QOL) of treatment-naive and treatment-experienced patients. <italic>Methods</italic>. A randomized controlled trial was conducted in the three largest public hospitals. Adherence was measured by self-completed questionnaires. QOL was assessed by the WHOQOL-HIV BREF. Outcomes were assessed at day 15, at 1, 2, and 3 months after start of treatment for treatment-naive patients and at 3 months after study enrollment for treatment-experienced patients. <italic>Results</italic>. A total of 103 treatment-naive and 93 treatment-experienced HIV/AIDS patients were consecutively recruited. Results show that a phone call intervention could maintain high self-reported adherence among both treatment-naive and treatment-experienced patients. After three months, significant QOL improvements were observed in domains of physical health (<italic>P</italic> = 0.003), level of independence (<italic>P</italic> = 0.018), environment (<italic>P</italic> = 0.002), and spirituality/religion/personal beliefs (<italic>P</italic> = 0.021) among treatment-naive patients. <italic>Conclusion</italic>. A mobile phone call intervention to patients could maintain high adherence rates although no statistically significant differences were found. A phone call could improve some domains of QOL among treatment-naive patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction </title><p>Since the beginning of the HIV/AIDS epidemic in 1981, nearly 30 million people have died from AIDS-related causes [<xref rid="B1" ref-type="bibr">1</xref>]. Antiretroviral therapy (ART) was initiated in 1996 and has contributed greatly to the reduction in mortality and morbidity among patients with HIV/AIDS [<xref rid="B2" ref-type="bibr">2</xref>]. The annual number of people dying from AIDS-related causes worldwide has been steadily decreasing from a peak of 2.2 million in 2005 to an estimated 1.8 million in 2010 [<xref rid="B3" ref-type="bibr">3</xref>]. In China, the mortality rate has decreased from 39.3 per 100 person-years in 2002 to 14.2 per 100 person-years in 2009 [<xref rid="B4" ref-type="bibr">4</xref>]. </p><p>While the benefits of ART are well established, poor adherence to the regimens is pervasive [<xref rid="B2" ref-type="bibr">2</xref>]. Nonadherence rates range from 30% to 40% in the United States of America, Latin America, and Europe [<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>], and in China, it is approximately 20% [<xref rid="B9" ref-type="bibr">9</xref>]. An adherence rate under 95% accounts for ART failure and results in drug resistance [<xref rid="B10" ref-type="bibr">10</xref>]. Thus, it is crucial for patients with HIV/AIDS to consistently comply with the regimen to decrease the risk of disease progression and drug resistance, maintaining CD4 lymphocyte count to prolong their survival and to achieve a better quality of life (QOL) [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>].</p><p>Mobile phone technology using text messages has been shown to be useful to improve adherence rates [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. However, patients sometimes do not receive the messages, or if they do, ignore them [<xref rid="B15" ref-type="bibr">15</xref>]. Previous studies reported that participants prefer interventions that not only act as a reminder but also as a useful source of information on HIV/AIDS as well as allowing them to enquire about their illness or simply to communicate with their providers [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. A phone call intervention [<xref rid="B17" ref-type="bibr">17</xref>] has been shown to have promising results in developed countries and has been suggested to be used to improve adherence to ART in resource-limited countries. </p><p>China is currently the world's largest mobile phone market [<xref rid="B18" ref-type="bibr">18</xref>], and approximately 76% of the population now own a mobile phone [<xref rid="B19" ref-type="bibr">19</xref>]. The present study was therefore carried out to investigate the effect of a phone call intervention to promote adherence to ART and QOL among HIV/AIDS patients in Baoshan, China.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Study Setting</title><p>Baoshan is located in the south western part of Yunnan, close to the Myanmar border, where HIV/AIDS is highly prevalent [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Baoshan prefecture began to monitor the HIV/AIDS epidemic in 1990. At present, the accumulative number of living cases is totally more than 4,500, and more than 1,500 patients have been under ART (Baoshan CDC internal statistics). This randomized controlled trial (RCT) was conducted in 3 out of 6 county hospitals in Baoshan Prefecture in 2011.</p></sec><sec id="sec2.2"><title>2.2. Study Sample</title><p>Based on the national guideline for ART in China [<xref rid="B22" ref-type="bibr">22</xref>], patients are indicated for ART when they have (1) a positive confirmatory test for HIV; (2) baseline CD4 count &#x0003c;350 cells/mm<sup>3</sup> or baseline WHO clinical staging of III or IV; (3) detailed history and physical examination. These patients were eligible to our study if they were (a) Chinese, (b) at least 18 years of age, (c) owning a mobile phone, (d) not imminently transferring to other hospitals, (e) not a prisoner, pregnant woman, or a hospitalized patient. Recruited patients were classified into two groups, treatment-naive patients and treatment-experienced patients. The latter group have been on treatment for 1 to 3 years. The required sample size was estimated to be at least 75 patients per study arm to detect an improvement of 20% in adherence rate from 75% to 95%, with 80% power, 95% confidence, and allowing for a 20% loss to followup. </p><p>Eligible patients were consecutively asked to participate in the study. Details of the study were given to patients who agreed to participate in the study, and verbal informed consent was obtained. Treatment-naive and treatment-experienced patients were allocated to either the intervention or control groups by the permuted block of two and four randomization method. The study arm assignment was concealed in an opaque-sealed envelope. If the phone call intervention was allocated, the patient then received information regarding the intervention for 3&#x02013;5 minutes by a well-trained registered nurse or health personnel.</p></sec><sec id="sec2.3"><title>2.3. Procedures</title><p>Two registered nurses or health personnel in each county hospital who had worked at the HIV/AIDS clinic were trained for 2 hours on usual care service including provision of ART information and instructions for taking medicine, general health care and self-management of symptoms related to HIV/AIDS and treatment, and relevant social support. Moreover, the nurse or health personnel who was designated to give the phone call intervention received counseling on stress-related problems, exploring patients' demands and expectations, and how to conduct a telephone appointment and interview, particularly regarding the privacy of the phone call and confidentiality of information. </p><p>On the first visit, patients were assessed on their baseline characteristics, attitudes, knowledge, and readiness for treatment by an interview. Relevant clinical information including CD4 count was obtained from the patient's medical record. QOL was examined by the WHOQOL-HIV BREF [<xref rid="B23" ref-type="bibr">23</xref>] to obtain six domains of QOL, namely, physical well-being, psychological status, level of independence, social relationships, environment and spirituality/religion/personal beliefs.</p></sec><sec id="sec2.4"><title>2.4. Intervention</title><p>All patients received usual care services including education on HIV/AIDS and treatment. Questions and health problems could be discussed with the doctor at the clinic. In addition to the usual care, patients in the intervention group were given a hospital phone number and a mobile phone number. The patient's mobile phone number(s) was also recorded. A test call was made, and the date and time for the telephone calls were designated to each patient. A reminder phone call was planned to be made every two weeks except for when a patient arrived for their scheduled follow-up visit. At the start of the call, the patient's name would be identified before any conversation begun. The conversation would be made in a friendly and private manner. A semistructured dialogue eliciting the reasons and difficulties in making a hospital visit, symptoms of treatment, treatment adherence, and difficulty in taking medication was used. Any questions and concerns about medication, health, and related issues were welcome for patients to ask. Each phone would take about 3 minutes. All phone calls and relevant conversation would be noted. If a patient did not answer the phone or another person answered the phone, or it was not convenient for a patient to talk, up to 4 calls on the same day, the call would be attempted later. A successful call referred to a patient was reached and conversation was made.</p></sec><sec id="sec2.5"><title>2.5. Followup</title><p>Based on the national guidelines for HIV/AIDS treatment [<xref rid="B22" ref-type="bibr">22</xref>], HIV/AIDS patients were appointed for followup at 15 days, at 1, 2, and 3 months, and then every three months after start of treatment. In this study, patients were followed up for 3 months as designated in the routine followup. Treatment adherence, symptoms related to HIV/AIDS, reasons for not taking medication, if any, QOL, and clinical information were obtained at every followup visit. CD4 count was obtained at baseline and at the 3-month follow-up visit only. Clinical information including treatment details such as WHO clinical stage and weight was obtained from the medical records.</p></sec><sec id="sec2.6"><title>2.6. Ethical Consideration</title><p>All participants were given details of the study, and verbal informed consent was obtained. Privacy and confidentiality were ensured. Data were kept in a locked drawer and were accessible for only responsible registered nurses or health personnel. The study was approved by the Ethics Committee, Faculty of Medicine, Prince of Songkla University, Thailand and Baoshan Prefecture Health Bureau, China. The study was registered to <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</ext-link>, NCT01395771.</p></sec><sec id="sec2.7"><title>2.7. Statistical Analysis</title><p>Descriptive statistics were used to compare baseline characteristics between intervention and control groups. Chi-square test or Fisher's exact test and Student's <italic>t</italic>-test were used to compare categorical variables and continuous variables between the two groups. Adherence rate in this study was computed by the percent of the prescribed drug 1 <italic>&#x02012;</italic> proportion pills missed &#x000d7; 100% [<xref rid="B17" ref-type="bibr">17</xref>]. McNemar's test was used to assess the change in proportion of WHO clinical staging of HIV/AIDS from pre- to postintervention. All data analysis was based on intention-to-treat. Data entry was entered in EpiData version 3.1 [<xref rid="B24" ref-type="bibr">24</xref>] and analysed by R version 2.14.0 [<xref rid="B25" ref-type="bibr">25</xref>]. </p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Flow of Participants</title><p>
<xref ref-type="fig" rid="fig1">Figure 1</xref> shows that among the 157 treatment-naive patients, 54 were excluded (11 ineligible, 43 refused to participate). Thus, 103 treatment-naive patients were recruited. Among 139 treatment-experienced patients, 46 were excluded (24 ineligible, 22 refused). Thus, 93 patients were recruited. The primary reasons for refusal to participate in the study were not having time and having transportation difficulties. After randomization, 52 and 51 treatment-naive, and 46 and 47 treatment-experienced patients were allocated to the intervention and control groups, respectively. The overall follow-up rates at day 15 and months 1, 2, and 3 for treatment-naive patients were 95.1%, 92.2%, 94.2%, and 87.3%, respectively, while the follow-up rate at 3 months among treatment-experienced patients was 88.2%. </p></sec><sec id="sec3.2"><title>3.2. Description of Participants</title><p>
<xref ref-type="table" rid="tab1">Table 1</xref> shows the comparison of baseline characteristics of participants between the intervention and control groups. Males and females were equally distributed among the two groups and most were aged between 20 and 40 years. Most were Han ethnicity, married or cohabiting, had at least a primary school education, were farmers, and resided in rural areas. The average annual income was below 10,000 Chinese yuan (CNY) (1,577 USD); however, one-third of treatment-naive patients in the control group had an annual income above 10,000 CNY. </p><p>Approximately 90% of all participants had a history of heterosexual contact, while only a few had a history of injecting drug use as a possible route of HIV infection. The average baseline CD4 count ranged from 200 to 350 cells/mm<sup>3</sup>; however, approximately one-third of treatment-experienced patients had a CD4 count above 350 cells/mm<sup>3</sup>. Most patients were WHO clinical stage I, and most patients received the standard regimen, AZT&#x02009;+&#x02009;3TC&#x02009;+&#x02009;NVP/EFV, for treatment.</p></sec><sec id="sec3.3"><title>3.3. Mobile Phone Calls</title><p>
<xref ref-type="table" rid="tab2">Table 2</xref> shows details of the bi-weekly phone calls made over the 12-week study period. A total of 231 and 564 phone calls were made for patients in the treatment-naive and treatment-experienced groups, respectively. The overall success rate for treatment-naive patients was 81.7%. The success rate was above 60% among treatment-experienced patients and was consistent across all call schedules. The average duration of phone calls was 2.9 &#x000b1; 1.9 minutes and 2.4 &#x000b1; 2.0 minutes in the treatment-naive and treatment-experienced groups, respectively. Conversations conducted over the phone were mostly related to clinical symptoms that patients had experienced recently and side-effects of their treatment.</p></sec><sec id="sec3.4"><title>3.4. Follow-Up Rate, Treatment Adherence, and Clinical Outcomes</title><p>
<xref ref-type="table" rid="tab3">Table 3</xref> compares the follow-up rates, self-reported adherence to treatment, CD4 count, and weight change between the two groups at each visit. The rates tended to be lower among treatment-naive patients, although no significant differences were observed. Among treatment-experienced patients, the 3-month follow-up rate was slightly higher in the intervention group, although, again, no significant difference was observed. The adherence rate among treatment-naive patients in the intervention group was consistently above 98%, whereas it fluctuated slightly in the control group. There were no statistically significant differences in adherence rate, mean CD4 count, weight change, WHO clinical staging, and opportunistic infections between the intervention and control groups in both treatment-naive and treatment-experienced patients.</p></sec><sec id="sec3.5"><title>3.5. Quality of Life</title><p>
<xref ref-type="table" rid="tab4">Table 4</xref> compares the mean WHO-QOL scores in 6 domains and change from baseline to month 3 between the two groups. In all QOL domains, the scores gradually improved over 3 months in both treatment-naive and treatment-experienced patients. Among treatment-naive patients, the mean QOL scores at baseline among the intervention and the control groups were similar. However, the scores after 3 months were significantly higher among patients who received the phone call intervention in domains of physical well-being, level of independence, environment, and spiritual/religious/personal beliefs. No significant differences in change in QOL scores were observed among the treatment-experienced patients.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Results of this RCT show that although a 3-minute mobile phone call intervention had no significant effect on the follow-up rate, adherence to treatment, and clinical outcomes, it could help maintain patient follow-up visits and treatment adherence. The adherence rates in the control group tended to decrease over time. After three months of intervention, significant improvements were observed in QOL domains for physical well-being, level of independence, environment, and spiritual/religion/personal beliefs among treatment-naive patients. </p><p>Many interventions have been trialed to promote and maintain adherence rates among patients with HIV/AIDS. Counseling and educational programs have shown to offer no or only minimal improvements to adherence rates [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>], while directly observed therapy (DOT) seems to offer no benefit over self-administered treatment [<xref rid="B28" ref-type="bibr">28</xref>]. Moreover, DOT is labor intensive, expensive, and can be perceived as intrusive [<xref rid="B29" ref-type="bibr">29</xref>]. Monetary incentives have been shown to offer positive reinforcement, but adherence rates are not sustained and return to baseline levels after discontinuation of the intervention [<xref rid="B30" ref-type="bibr">30</xref>]. </p><p>Subsequently, a variety of electronic devices, such as pagers [<xref rid="B31" ref-type="bibr">31</xref>], disease management assistance system (DMAS) [<xref rid="B32" ref-type="bibr">32</xref>], electronic pill-cap [<xref rid="B33" ref-type="bibr">33</xref>], and alarms, have been used to regularly remind patients to take their medication [<xref rid="B34" ref-type="bibr">34</xref>]. A recent systematic review [<xref rid="B35" ref-type="bibr">35</xref>] confirmed that these devices may result in improved adherence to ART. However, these devices have drawbacks, including inconvenience, high cost, and patient dissatisfaction due to privacy concerns [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. Moreover, the devices solely serve as a reminder and do not cope with potential adherence barriers, including management of side effects, provision of social support, and allowing the patient to discuss their health problems. </p><p>A previous randomized trial in the USA [<xref rid="B38" ref-type="bibr">38</xref>] on a scripted serial landline telephone call among treatment-naive HIV/AIDS patients over 96 weeks showed higher self-reported adherence rates in the telephone group but no statistically significant improvements in virologic outcomes. A subsequent randomized trial in the USA [<xref rid="B17" ref-type="bibr">17</xref>] assessing the effect of an 8-minute landline telephone call among treatment-naive patients showed a significantly higher adherence rate at week 64 in the telephone group as well as being able to maintain high adherence rates over time. </p><p>Recently, mobile technology for health (mHealth), such as mobile phone use, is a new promising innovative option in health care [<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>]. It can surmount barriers such as stigma, loss of privacy, and transportation limitations associated with traditional interventions [<xref rid="B13" ref-type="bibr">13</xref>]. The feasibility of mobile phone use in health care among patients with HIV/AIDS has been demonstrated in both developed and resource-limited countries [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>]. Mobile phone technology can offer medication reminders via a short message service, voice call, dissemination of information, and communication with health workers. However, some studies [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B44" ref-type="bibr">44</xref>] have reported that a reminder can easily be ignored. Patients prefer to obtain information and be given the opportunity to communicate with health workers. </p><p>Our study is one of the first RCTs to assess mobile phone use [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>] on adherence rates among patients with HIV/AIDS. A weekly mobile phone message over 12 months in Kenya [<xref rid="B14" ref-type="bibr">14</xref>] was found to improve patient adherence rates. Two other protocols [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>] are currently in progress, and the results will hopefully offer a better understanding of the use of this technology. In addition to reminding services as provided in other RCTs [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>], our study offered a combination of reminder, information dissemination, and communication with health workers through a biweekly mobile phone call service. Although adherence rates were not significantly better in the intervention group, they were sustained across all follow-up visits among treatment-naive patients. The usefulness of mobile phone intervention may thus be confined to treatment-naive patients. Those patients lack knowledge and experience in ART and self-care and have not yet developed their own coping mechanisms, unlike treatment-experienced patients. The questions most commonly asked by patients related to symptoms experienced, such as poor appetite, fever, fatigue, side-effects and toxicity of the treatment, and problems with opportunistic infection. Similarly, a previous pilot study [<xref rid="B44" ref-type="bibr">44</xref>] on mobile phone surveys for HIV/AIDS care in southern India reported that most calls were related to ART toxicity, ART initiation, and management of opportunistic infections. </p><p>In addition to adherence rate, QOL is an important concern in health care and treatment provision. While many electronic devices have been invented, primarily to improve adherence rates, they showed no improvement in QOL [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. For example, the DMAS [<xref rid="B37" ref-type="bibr">37</xref>] provides a verbal reminder of the medication time but results in deterioration of the patient's QOL which may be due to a violation of the patient's privacy by the reminder, explained by the authors. </p><p>QOL has not yet been evaluated in other RCTs where mobile phone use was used as the intervention [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>], whereas the mobile phone call in our study supported a better QOL among treatment-naive patients. Similarly, a recent intervention study investigating home visits and a telephone intervention conducted in China [<xref rid="B46" ref-type="bibr">46</xref>] reported improvement of adherence rate and QOL for physical, psychological, social, and environmental domains. Stand-alone devices which provide reminders but lack the ability to allow patients to communicate with health personnel may improve adherence rates, but they cannot improve the QOL of patients with HIV/AIDS. Previous studies [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>] reported that patients prefer interventions which not only act as a reminder but also provide a source of useful information on HIV/AIDS as well as allowing them to communicate with healthcare providers. </p><p>Although this study had a strong study design, the sample size was too small to detect differences in adherence rates between the intervention and the control groups. The post hoc power of the study ranged from only 40% to 60% across follow-up visits. High self-reported adherence rates in our study were observed in both the intervention and control groups. Although the high adherence to ART in China has also been reported in another study [<xref rid="B47" ref-type="bibr">47</xref>], this may also be a result of the Hawthorn effect where patients tend to modify their behaviors or response under close observation and assessment while participating in a study. Due to budget constraints, viral loads were too expensive to be monitored. A larger study with longer follow-up duration assessing adherence to treatment, QOL, and cost-effectiveness should be conducted to tailor the most suitable intervention in this setting.</p></sec></body><back><ack><title>Conflict of Interests</title><p>The authors declare that they have no financial conflict of interests.</p></ack><ack><title>Acknowledgments</title><p>The authors would like to thank the nurses, health personnel, and all participants who kindly cooperated with the researchers in the study. </p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="other"><collab>UNAIDS</collab><article-title>Unite for universal access: Overview brochure on 2011 High Level Meeting on AIDS</article-title><comment>New York, NY, USA, Joint United Nations Programme on HIV/AIDS, 2011</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>NR</given-names></name></person-group><article-title>Adherence to antiretroviral therapies: state of the science</article-title><source><italic>Current HIV Research</italic></source><year>2004</year><volume>2</volume><issue>3</issue><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="other">2-s2.0-3042758020</pub-id><pub-id pub-id-type="pmid">15279584</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><collab>WHO</collab><article-title>Global HIV/AIDS response: epidemic update and health sector progress towards universal access:progress report</article-title><comment>The World Health Orgnization, Geneva, Switzerland, 2011</comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Dou</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study</article-title><source><italic>The Lancet Infectious Diseases</italic></source><year>2011</year><volume>11</volume><issue>7</issue><fpage>516</fpage><lpage>524</lpage><pub-id pub-id-type="other">2-s2.0-79959311099</pub-id><pub-id pub-id-type="pmid">21600849</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>KM</given-names></name><name><surname>Carrington</surname><given-names>D</given-names></name><name><surname>Duncan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluation of adherence to highly active antiretroviral therapy in adults in Jamaica</article-title><source><italic>West Indian Medical Journal</italic></source><year>2008</year><volume>57</volume><issue>3</issue><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="other">2-s2.0-55749094472</pub-id><pub-id pub-id-type="pmid">19583131</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JA</given-names></name></person-group><article-title>Addressing the challenges of adherence</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2002</year><volume>29</volume><issue>supplement 1</issue><fpage>S2</fpage><lpage>S10</lpage><pub-id pub-id-type="other">2-s2.0-0036471409</pub-id><pub-id pub-id-type="pmid">11832696</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duran</surname><given-names>S</given-names></name><name><surname>Saves</surname><given-names>M</given-names></name><name><surname>Spire</surname><given-names>B</given-names></name><etal/></person-group><article-title>Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy</article-title><source><italic>AIDS</italic></source><year>2001</year><volume>15</volume><fpage>2441</fpage><lpage>2444</lpage><pub-id pub-id-type="pmid">11740195</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwkerk</surname><given-names>PT</given-names></name><name><surname>Sprangers</surname><given-names>MAG</given-names></name><name><surname>Burger</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study</article-title><source><italic>Archives of Internal Medicine</italic></source><year>2001</year><volume>161</volume><issue>16</issue><fpage>1962</fpage><lpage>1968</lpage><pub-id pub-id-type="other">2-s2.0-0035840315</pub-id><pub-id pub-id-type="pmid">11525698</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><article-title>Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China</article-title><source><italic>AIDS</italic></source><year>2007</year><volume>21</volume><issue>supplement 8</issue><fpage>S149</fpage><lpage>S155</lpage><pub-id pub-id-type="other">2-s2.0-37549041652</pub-id><pub-id pub-id-type="pmid">18172384</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesney</surname><given-names>M</given-names></name></person-group><article-title>Adherence to HAART regimens</article-title><source><italic>AIDS Patient Care and STDs</italic></source><year>2003</year><volume>17</volume><issue>4</issue><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="other">2-s2.0-0037391631</pub-id><pub-id pub-id-type="pmid">12737640</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Hogg</surname><given-names>RS</given-names></name><name><surname>Yip</surname><given-names>B</given-names></name><name><surname>Harrigan</surname><given-names>PR</given-names></name><name><surname>O&#x02019;Shaughnessy</surname><given-names>MV</given-names></name><name><surname>Montaner</surname><given-names>JS</given-names></name></person-group><article-title>Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2003</year><volume>139</volume><issue>10</issue><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="other">2-s2.0-0346170054</pub-id><pub-id pub-id-type="pmid">14623618</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannheimer</surname><given-names>SB</given-names></name><name><surname>Matts</surname><given-names>J</given-names></name><name><surname>Telzak</surname><given-names>E</given-names></name><etal/></person-group><article-title>Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence</article-title><source><italic>AIDS Care</italic></source><year>2005</year><volume>17</volume><issue>1</issue><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="other">2-s2.0-12944277038</pub-id><pub-id pub-id-type="pmid">15832830</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shet</surname><given-names>A</given-names></name><name><surname>Arumugam</surname><given-names>K</given-names></name><name><surname>Rodrigues</surname><given-names>R</given-names></name><etal/></person-group><article-title>Designing a mobile phone-based intervention to promote adherence to antiretroviral therapy in South India</article-title><source><italic>AIDS and Behavior</italic></source><year>2010</year><volume>14</volume><issue>3</issue><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="other">2-s2.0-77956870637</pub-id><pub-id pub-id-type="pmid">20054634</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>RT</given-names></name><name><surname>Ritvo</surname><given-names>P</given-names></name><name><surname>Mills</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial</article-title><source><italic>The Lancet</italic></source><year>2010</year><volume>376</volume><issue>9755</issue><fpage>1838</fpage><lpage>1845</lpage><pub-id pub-id-type="other">2-s2.0-78649456108</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidney</surname><given-names>K</given-names></name><name><surname>Antony</surname><given-names>J</given-names></name><name><surname>Rodrigues</surname><given-names>R</given-names></name><etal/></person-group><article-title>Supporting patient adherence to antiretrovirals using mobile phone reminders: patient responses from South India</article-title><source><italic>AIDS Care</italic></source><year>2012</year><volume>24</volume><issue>5</issue><fpage>612</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">22150088</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curioso</surname><given-names>WH</given-names></name><name><surname>Kurth</surname><given-names>AE</given-names></name></person-group><article-title>Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru</article-title><source><italic>BMC Medical Informatics and Decision Making</italic></source><year>2007</year><volume>7, article 24</volume><pub-id pub-id-type="other">2-s2.0-35748973852</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>NR</given-names></name><name><surname>Testa</surname><given-names>MA</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><etal/></person-group><article-title>Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2008</year><volume>47</volume><issue>1</issue><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="other">2-s2.0-39049143783</pub-id><pub-id pub-id-type="pmid">17891043</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="other"><article-title>China to surpass 1 billion mobile connections in May 2012</article-title><comment>News related to ITU Telecommunication/ICT Statistics, 26 July 2011, <ext-link ext-link-type="uri" xlink:href="http://www.itu.int/ITU-D/ict/newslog/China.aspx">http://www.itu.int/ITU-D/ict/newslog/China.aspx</ext-link></comment></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="other"><article-title>The Progression of Main Indicators in Communications Industry in February, 2012</article-title><comment>Ministry of Industry and Information Technology of China, 2012, <ext-link ext-link-type="uri" xlink:href="http://www.miit.gov.cn/n11293472/index.html">http://www.miit.gov.cn/n11293472/index.html</ext-link></comment></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WCW</given-names></name><name><surname>Yilin</surname><given-names>W</given-names></name></person-group><article-title>A qualitative study on HIV risk behaviors and medical needs of sex workers in a China/Myanmar border town</article-title><source><italic>AIDS Patient Care and STDs</italic></source><year>2003</year><volume>17</volume><issue>8</issue><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="other">2-s2.0-0041886814</pub-id><pub-id pub-id-type="pmid">13678543</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Caouette</surname><given-names>TM</given-names></name></person-group><article-title>Small Dreams Beyond Reach: The Lives of Migrant Children and Yout Along the Borders of China, Myanmar and Thailand</article-title><comment>A Participatory Action Research Project of Save the Children, UK, 2001, <ext-link ext-link-type="uri" xlink:href="http://www.humantrafficking.org/publications/164">http://www.humantrafficking.org/publications/164</ext-link></comment></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><collab>Ministry of Health of China Expert Panel on AIDS Clinical Practices</collab><source><italic>The Manul of National Free Antiretroviral Therapy</italic></source><year>2007</year><edition>2nd edition</edition><publisher-loc>Beijing, China</publisher-loc><publisher-name>People's Health Publishing House</publisher-name></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="other"><collab>WHO</collab><article-title>WHOQOL-HIV BREF, Geneva, Switzerland</article-title><comment>Mental Health: Evidence and Research Department of Mental Health and Substance Dependence, 1999</comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="other"><article-title>Epidata [computer program]</article-title><comment>Version 3. 1. Odense: The Epidata Association, 2008</comment></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><article-title>R [A Language and Environment for Statictical Computing]</article-title><comment>Version 2. 14. 0. Vienna, Austria, R Development Core Team, 2011</comment></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawlings</surname><given-names>MK</given-names></name><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Farthing</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2003</year><volume>34</volume><issue>2</issue><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="other">2-s2.0-0141923763</pub-id><pub-id pub-id-type="pmid">14526206</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remien</surname><given-names>RH</given-names></name><name><surname>Stirratt</surname><given-names>MJ</given-names></name><name><surname>Dolezal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Couple-focused support to improve HIV medication adherence: a randomized controlled trial</article-title><source><italic>AIDS</italic></source><year>2005</year><volume>19</volume><issue>8</issue><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="other">2-s2.0-20644442474</pub-id><pub-id pub-id-type="pmid">15867495</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>N</given-names></name><name><surname>Nachega</surname><given-names>JB</given-names></name><name><surname>Engel</surname><given-names>ME</given-names></name><name><surname>Mills</surname><given-names>EJ</given-names></name></person-group><article-title>Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials</article-title><source><italic>The Lancet</italic></source><year>2009</year><volume>374</volume><issue>9707</issue><fpage>2064</fpage><lpage>2071</lpage><pub-id pub-id-type="other">2-s2.0-72049114441</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechty</surname><given-names>CA</given-names></name><name><surname>Bangsberg</surname><given-names>DR</given-names></name></person-group><article-title>Doubts about DOT: antiretroviral therapy for resource-poor countries</article-title><source><italic>AIDS</italic></source><year>2003</year><volume>17</volume><issue>9</issue><fpage>1383</fpage><lpage>1387</lpage><pub-id pub-id-type="other">2-s2.0-0037999039</pub-id><pub-id pub-id-type="pmid">12799560</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigsby</surname><given-names>MO</given-names></name><name><surname>Rosen</surname><given-names>MI</given-names></name><name><surname>Beauvais</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention</article-title><source><italic>Journal of General Internal Medicine</italic></source><year>2000</year><volume>15</volume><issue>12</issue><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="other">2-s2.0-0034530290</pub-id><pub-id pub-id-type="pmid">11119180</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>JM</given-names></name><name><surname>Huh</surname><given-names>D</given-names></name><name><surname>Frick</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Peer support and pager messaging to promote antiretroviral modifying therapy in seattle: a randomized controlled trial</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2009</year><volume>52</volume><issue>4</issue><fpage>465</fpage><lpage>473</lpage><pub-id pub-id-type="other">2-s2.0-74049146700</pub-id><pub-id pub-id-type="pmid">19911481</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>ASA</given-names></name><name><surname>McGruder</surname><given-names>HF</given-names></name><name><surname>Wu</surname><given-names>AW</given-names></name><etal/></person-group><article-title>A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2005</year><volume>41</volume><issue>6</issue><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="other">2-s2.0-24644507807</pub-id><pub-id pub-id-type="pmid">16107989</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safren</surname><given-names>SA</given-names></name><name><surname>Hendriksen</surname><given-names>ES</given-names></name><name><surname>Desousa</surname><given-names>N</given-names></name><name><surname>Boswell</surname><given-names>SL</given-names></name><name><surname>Mayer</surname><given-names>KH</given-names></name></person-group><article-title>Use of an on-line pager system to increase adherence to antiretroviral medications</article-title><source><italic>AIDS Care</italic></source><year>2003</year><volume>15</volume><issue>6</issue><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="other">2-s2.0-0344735833</pub-id><pub-id pub-id-type="pmid">14617500</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannheimer</surname><given-names>SB</given-names></name><name><surname>Morse</surname><given-names>E</given-names></name><name><surname>Matts</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Sustained benefit from a long-term antiretroviral adherence intervention: results of a large randomized clinical trial</article-title><source><italic>Journal of Acquired Immune Deficiency Syndromes</italic></source><year>2006</year><volume>43</volume><issue>supplement 1</issue><fpage>S41</fpage><lpage>S47</lpage><pub-id pub-id-type="other">2-s2.0-33845367426</pub-id><pub-id pub-id-type="pmid">17091022</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saberi</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>MO</given-names></name></person-group><article-title>Technology-based self-care methods of improving antiretroviral adherence: a systematic review</article-title><source><italic>PLoS One</italic></source><year>2011</year><volume>6</volume><pub-id pub-id-type="publisher-id">e27533</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>D</given-names></name><name><surname>Hermann</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Berkovitch</surname><given-names>M</given-names></name><name><surname>Olivieri</surname><given-names>N</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator</article-title><source><italic>Journal of Clinical Pharmacology</italic></source><year>1994</year><volume>34</volume><issue>9</issue><fpage>944</fpage><lpage>949</lpage><pub-id pub-id-type="other">2-s2.0-0027995478</pub-id><pub-id pub-id-type="pmid">7983239</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>AW</given-names></name><name><surname>Snyder</surname><given-names>CF</given-names></name><name><surname>Huang</surname><given-names>IC</given-names></name><etal/></person-group><article-title>A randomized trial of the impact of a programmable medication reminder device on quality of life in patients with AIDS</article-title><source><italic>AIDS Patient Care and STDs</italic></source><year>2006</year><volume>20</volume><issue>11</issue><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="other">2-s2.0-33845465431</pub-id><pub-id pub-id-type="pmid">17134351</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collier</surname><given-names>AC</given-names></name><name><surname>Ribaudo</surname><given-names>H</given-names></name><name><surname>Mukherjee</surname><given-names>AL</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><name><surname>Fischl</surname><given-names>MA</given-names></name><name><surname>Chesney</surname><given-names>M</given-names></name></person-group><article-title>A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>2005</year><volume>192</volume><issue>8</issue><fpage>1398</fpage><lpage>1406</lpage><pub-id pub-id-type="other">2-s2.0-25844435301</pub-id><pub-id pub-id-type="pmid">16170757</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>WA</given-names></name></person-group><article-title>Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries?</article-title><source><italic>Globalization and Health</italic></source><year>2006</year><volume>2, article 9</volume><pub-id pub-id-type="other">2-s2.0-33746832078</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>R</given-names></name><name><surname>Karanja</surname><given-names>S</given-names></name></person-group><article-title>Mobile phones: exceptional tools for HIV/AIDS, health, and crisis management</article-title><source><italic>The Lancet Infectious Diseases</italic></source><year>2008</year><volume>8</volume><issue>12</issue><fpage>738</fpage><lpage>739</lpage><pub-id pub-id-type="other">2-s2.0-56049106838</pub-id><pub-id pub-id-type="pmid">19022188</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Costa</surname><given-names>A</given-names></name><name><surname>Shet</surname><given-names>A</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><etal/></person-group><article-title>Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India&#x02014;the HIVIND study protocol</article-title><source><italic>BMC Medical Research Methodology</italic></source><year>2010</year><volume>10, article 25</volume><pub-id pub-id-type="other">2-s2.0-77951584070</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunutsor</surname><given-names>S</given-names></name><name><surname>Walley</surname><given-names>J</given-names></name><name><surname>Katabira</surname><given-names>E</given-names></name><etal/></person-group><article-title>Using mobile phones to improve clinic attendance amongst an antiretroviral treatment cohort in rural Uganda: a cross-sectional and prospective study</article-title><source><italic>AIDS and Behavior</italic></source><year>2010</year><volume>14</volume><issue>6</issue><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="other">2-s2.0-79952277472</pub-id><pub-id pub-id-type="pmid">20700644</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puccio</surname><given-names>JA</given-names></name><name><surname>Belzer</surname><given-names>M</given-names></name><name><surname>Olson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study</article-title><source><italic>AIDS Patient Care and STDs</italic></source><year>2006</year><volume>20</volume><issue>6</issue><fpage>438</fpage><lpage>444</lpage><pub-id pub-id-type="other">2-s2.0-33745622698</pub-id><pub-id pub-id-type="pmid">16789857</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manoharan</surname><given-names>G</given-names></name><name><surname>Dharmarajan</surname><given-names>S</given-names></name><name><surname>Ramalingam</surname><given-names>PK</given-names></name><name><surname>Mathew</surname><given-names>S</given-names></name><name><surname>Varghese</surname><given-names>JC</given-names></name></person-group><article-title>Mobile phone communication and health system strengthening: a pilot study of telephonic warmline consultation in HIV care and support in South India</article-title><source><italic>Journal of the International Association of Physicians in AIDS Care</italic></source><year>2012</year><volume>11</volume><issue>3</issue><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">22357374</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mbuagbaw</surname><given-names>L</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Ongolo-Zogo</surname><given-names>P</given-names></name><etal/></person-group><article-title>The cameroon mobile phone sms (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy</article-title><source><italic>Trials</italic></source><year>2011</year><volume>12, article 5</volume><pub-id pub-id-type="other">2-s2.0-78650945996</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fennie</surname><given-names>KP</given-names></name><name><surname>Williams</surname><given-names>AB</given-names></name></person-group><article-title>Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China</article-title><source><italic>Journal of Clinical Nursing</italic></source><year>2010</year><volume>19</volume><issue>3-4</issue><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="other">2-s2.0-74549209576</pub-id><pub-id pub-id-type="pmid">20500277</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>WT</given-names></name><name><surname>Huh</surname><given-names>D</given-names></name><etal/></person-group><article-title>A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China</article-title><source><italic>AIDS and Behavior</italic></source><year>2011</year><volume>15</volume><fpage>919</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">20957423</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow chart of study participants.</p></caption><graphic xlink:href="ART2013-580974.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study participants in intervention and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Participant characteristic</th><th align="center" colspan="2" rowspan="1">Treatment-naive</th><th align="center" colspan="2" rowspan="1">Treatment-experienced</th></tr><tr><th align="center" rowspan="1" colspan="1">Intervention (<italic>n</italic> = 52)</th><th align="center" rowspan="1" colspan="1">Control (<italic>n</italic> = 51)</th><th align="center" rowspan="1" colspan="1">Intervention (<italic>n</italic> = 46)</th><th align="center" rowspan="1" colspan="1">Control (<italic>n</italic> = 47)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">24 (46.2)</td><td align="center" rowspan="1" colspan="1"> 27 (52.9)</td><td align="center" rowspan="1" colspan="1">22 (47.8)</td><td align="center" rowspan="1" colspan="1">21 (44.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; Female</td><td align="center" rowspan="1" colspan="1">28 (53.8)</td><td align="center" rowspan="1" colspan="1"> 24 (47.1)</td><td align="center" rowspan="1" colspan="1">24 (52.2)</td><td align="center" rowspan="1" colspan="1">26 (55.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age group (years)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;20&#x02013;40</td><td align="center" rowspan="1" colspan="1">38 (73.1)</td><td align="center" rowspan="1" colspan="1"> 39 (76.5)</td><td align="center" rowspan="1" colspan="1">32 (69.6)</td><td align="center" rowspan="1" colspan="1">34 (72.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;40&#x02013;60</td><td align="center" rowspan="1" colspan="1">14 (26.9)</td><td align="center" rowspan="1" colspan="1"> 10 (19.6)</td><td align="center" rowspan="1" colspan="1">13 (28.3)</td><td align="center" rowspan="1" colspan="1">13 (27.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;60</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1"> 2 (3.9)</td><td align="center" rowspan="1" colspan="1">1 (2.2)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Han </td><td align="center" rowspan="1" colspan="1">41 (78.8)</td><td align="center" rowspan="1" colspan="1"> 49 (96.1)</td><td align="center" rowspan="1" colspan="1">41 (89.1)</td><td align="center" rowspan="1" colspan="1">40 (85.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other </td><td align="center" rowspan="1" colspan="1">11 (21.2)</td><td align="center" rowspan="1" colspan="1"> 2 (3.9)</td><td align="center" rowspan="1" colspan="1">5 (10.9)</td><td align="center" rowspan="1" colspan="1">7 (14.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Marital status (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Single</td><td align="center" rowspan="1" colspan="1">3 (5.8)</td><td align="center" rowspan="1" colspan="1"> 2 (3.9)</td><td align="center" rowspan="1" colspan="1">3 (6.5)</td><td align="center" rowspan="1" colspan="1">2 (4.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Married/cohabiting</td><td align="center" rowspan="1" colspan="1">44 (84.6)</td><td align="center" rowspan="1" colspan="1"> 46 (90.2)</td><td align="center" rowspan="1" colspan="1"> 41 (89.1)</td><td align="center" rowspan="1" colspan="1">39 (83.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divorced/widowed</td><td align="center" rowspan="1" colspan="1">5 (9.6)</td><td align="center" rowspan="1" colspan="1"> 3 (5.9)</td><td align="center" rowspan="1" colspan="1">2 (4.3)</td><td align="center" rowspan="1" colspan="1">6 (12.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education level (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;None</td><td align="center" rowspan="1" colspan="1">4 (7.7)</td><td align="center" rowspan="1" colspan="1">3 (5.9)</td><td align="center" rowspan="1" colspan="1">3 (6.5)</td><td align="center" rowspan="1" colspan="1">3 (6.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Primary school</td><td align="center" rowspan="1" colspan="1">21 (40.4)</td><td align="center" rowspan="1" colspan="1"> 24 (47.1)</td><td align="center" rowspan="1" colspan="1">14 (30.4)</td><td align="center" rowspan="1" colspan="1">18 (38.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Junior high school</td><td align="center" rowspan="1" colspan="1">24 (46.2)</td><td align="center" rowspan="1" colspan="1"> 19 (37.3)</td><td align="center" rowspan="1" colspan="1">22 (47.8)</td><td align="center" rowspan="1" colspan="1">20 (42.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;High school or above</td><td align="center" rowspan="1" colspan="1">3 (5.8)</td><td align="center" rowspan="1" colspan="1">5 (9.8)</td><td align="center" rowspan="1" colspan="1">7 (15.2)</td><td align="center" rowspan="1" colspan="1">6 (12.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Occupation (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Agriculture</td><td align="center" rowspan="1" colspan="1">44 (84.6)</td><td align="center" rowspan="1" colspan="1"> 41 (80.4)</td><td align="center" rowspan="1" colspan="1">37 (80.4)</td><td align="center" rowspan="1" colspan="1">37 (78.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Business</td><td align="center" rowspan="1" colspan="1">6 (11.5)</td><td align="center" rowspan="1" colspan="1">7 (13.7)</td><td align="center" rowspan="1" colspan="1">3 (6.5)</td><td align="center" rowspan="1" colspan="1">2 (4.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other </td><td align="center" rowspan="1" colspan="1">2 (3.8)</td><td align="center" rowspan="1" colspan="1">3 (5.9)</td><td align="center" rowspan="1" colspan="1">6 (13.0)</td><td align="center" rowspan="1" colspan="1">8 (17.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Residential area (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rural </td><td align="center" rowspan="1" colspan="1">47 (90.4)</td><td align="center" rowspan="1" colspan="1">48 (92.3)</td><td align="center" rowspan="1" colspan="1">39 (84.8)</td><td align="center" rowspan="1" colspan="1">43 (91.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urban </td><td align="center" rowspan="1" colspan="1">5 (9.6)</td><td align="center" rowspan="1" colspan="1">4 (7.7)</td><td align="center" rowspan="1" colspan="1">7 (15.2)</td><td align="center" rowspan="1" colspan="1">4 (8.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Annual income (CNY)<sup>a</sup>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;2000</td><td align="center" rowspan="1" colspan="1">22 (42.3)</td><td align="center" rowspan="1" colspan="1">18 (35.3)</td><td align="center" rowspan="1" colspan="1">14 (30.4)</td><td align="center" rowspan="1" colspan="1">9 (19.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2000&#x02013;10000</td><td align="center" rowspan="1" colspan="1">21 (40.4)</td><td align="center" rowspan="1" colspan="1">15 (29.4)</td><td align="center" rowspan="1" colspan="1">24 (52.2)</td><td align="center" rowspan="1" colspan="1">31 (66)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;10000</td><td align="center" rowspan="1" colspan="1">9 (17.3)</td><td align="center" rowspan="1" colspan="1">18 (35.3)</td><td align="center" rowspan="1" colspan="1"> 8 (17.4)</td><td align="center" rowspan="1" colspan="1">7 (14.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Transmission route (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heterosexual </td><td align="center" rowspan="1" colspan="1">46 (88.5)</td><td align="center" rowspan="1" colspan="1">42 (82.4)</td><td align="center" rowspan="1" colspan="1">43 (93.5)</td><td align="center" rowspan="1" colspan="1">44 (93.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Injecting drug use</td><td align="center" rowspan="1" colspan="1">6 (11.5)</td><td align="center" rowspan="1" colspan="1">8 (15.7)</td><td align="center" rowspan="1" colspan="1">2 (4.3)</td><td align="center" rowspan="1" colspan="1">5 (10.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other </td><td align="center" rowspan="1" colspan="1">4 (7.7)</td><td align="center" rowspan="1" colspan="1">8 (15.7)</td><td align="center" rowspan="1" colspan="1">1 (2.2)</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count (cells/mm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;100</td><td align="center" rowspan="1" colspan="1">12 (23.1)</td><td align="center" rowspan="1" colspan="1"> 9 (17.6)</td><td align="center" rowspan="1" colspan="1"> 2 (4.4)</td><td align="center" rowspan="1" colspan="1">1 (2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;100&#x02013;200</td><td align="center" rowspan="1" colspan="1">13 (25.0)</td><td align="center" rowspan="1" colspan="1">10 (19.6)</td><td align="center" rowspan="1" colspan="1"> 10 (22.2)</td><td align="center" rowspan="1" colspan="1">8 (17.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;200&#x02013;350</td><td align="center" rowspan="1" colspan="1">27 (51.9)</td><td align="center" rowspan="1" colspan="1">32 (62.7)</td><td align="center" rowspan="1" colspan="1">18 (40)</td><td align="center" rowspan="1" colspan="1">21 (46.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;350</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1"> 15 (33.3)</td><td align="center" rowspan="1" colspan="1">15 (33.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO clinical staging (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;I </td><td align="center" rowspan="1" colspan="1">30 (57.7)</td><td align="center" rowspan="1" colspan="1">36 (70.6)</td><td align="center" rowspan="1" colspan="1">26 (56.5)</td><td align="center" rowspan="1" colspan="1">22 (46.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;II </td><td align="center" rowspan="1" colspan="1">10 (19.2)</td><td align="center" rowspan="1" colspan="1"> 6 (11.8)</td><td align="center" rowspan="1" colspan="1"> 6 (13.0)</td><td align="center" rowspan="1" colspan="1">12 (25.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;III or IV</td><td align="center" rowspan="1" colspan="1">12 (23.1)</td><td align="center" rowspan="1" colspan="1"> 9 (17.6)</td><td align="center" rowspan="1" colspan="1">14 (30.4)</td><td align="center" rowspan="1" colspan="1">13 (27.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">ART regimen (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AZT + 3TC + EFV<sup>b</sup>
</td><td align="center" rowspan="1" colspan="1">19 (36.5)</td><td align="center" rowspan="1" colspan="1">15 (29.4)</td><td align="center" rowspan="1" colspan="1"> 9 (19.6)</td><td align="center" rowspan="1" colspan="1">11 (23.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AZT + 3TC + NVP<sup>c</sup>
</td><td align="center" rowspan="1" colspan="1">28 (53.8)</td><td align="center" rowspan="1" colspan="1">31 (60.8)</td><td align="center" rowspan="1" colspan="1">26 (56.5)</td><td align="center" rowspan="1" colspan="1">23 (48.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other </td><td align="center" rowspan="1" colspan="1">5 (9.6)</td><td align="center" rowspan="1" colspan="1">5 (9.8)</td><td align="center" rowspan="1" colspan="1">11 (23.9)</td><td align="center" rowspan="1" colspan="1">13 (27.7)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>
a</sup>1 USD = 6.36&#x02009;CNY; <sup>b,c</sup>AZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; ART: antiretroviral therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Details of the biweekly phone calls made over the 12-week study period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th colspan="3" align="center" rowspan="1">Treatment-naive patients</th><th colspan="3" align="center" rowspan="1">Treatment-experienced patients</th></tr><tr><th align="left" rowspan="1" colspan="1">Phone call appointment </th><th align="center" rowspan="1" colspan="1">No. of patients requiring a phone<break/>call <italic>n</italic> = 52</th><th align="center" rowspan="1" colspan="1">No. of successful calls&#x02009;<break/>
<italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Call time (min)<break/>(mean &#x000b1; SD)</th><th align="center" rowspan="1" colspan="1">No. of patients requiring a phone<break/>call <italic>n</italic> = 46</th><th align="center" rowspan="1" colspan="1">No. of successful calls<break/>
<italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Call time (min)<break/>(mean &#x000b1; SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Day 15</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2 (66.0)</td><td align="center" rowspan="1" colspan="1">4.7 &#x000b1; 1.2</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">32 (69.6)</td><td align="center" rowspan="1" colspan="1">2.5 &#x000b1; 2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">3 (75.0)</td><td align="center" rowspan="1" colspan="1">6.0 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">30 (65.2)</td><td align="center" rowspan="1" colspan="1">2.3 &#x000b1; 2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 1.5</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">46 (90.2)</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">28 (60.9)</td><td align="center" rowspan="1" colspan="1">2.2 &#x000b1; 1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">2 (33.3)</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">29 (63.4)</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 2.5</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">44 (86.2)</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">29 (63.4)</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (20.0)</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1"> 6 (100.0)</td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 1.3</td></tr><tr><td align="left" colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">98 (81.7)</td><td align="center" rowspan="1" colspan="1">2.9 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">236</td><td align="center" rowspan="1" colspan="1">154 (65.3)</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 2.0</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Follow-up rate, self-reported adherence to treatment, CD4, and weight change between intervention and control groups over time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Treatment-naive patients</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Treatment-experienced patients</th><th align="center" rowspan="1" colspan="1">&#x02009;</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Group</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Group</th><th align="center" rowspan="1" colspan="1">&#x02009;</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic> value</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Control</th></tr></thead><tbody><tr><td colspan="11" align="center" rowspan="1">Follow-up rate (%)</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Visit 1</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1"> 94.2</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1"> 94.1</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">91.3</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">97.9</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Visit 2</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1"> 92.3</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1"> 92.2</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visit 3</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1"> 92.3</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1"> 94.2</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Visit 4</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1"> 90.3</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1"> 84.3</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">95.7</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">93.6</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Self-reported adherence, mean (SD)</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">99.2 (2.3)</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">99.1 (2.5)</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Day 15</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">98.9 (3.9)</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">97.3 (11.2)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 1</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">98.7 (5.3)</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">94.7 (22.5)</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 2</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">99.8 (0.8)</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">97.0 (17.2)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">99.7 (1.6)</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">96.5 (17.8)</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">99.6 (1.0)</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">99.5 (2.0)</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">CD4 (cell count/mm<sup>3</sup>) mean (SD)</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">191 (99.6)</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">216 (98.2)</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">286 (129.7)</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">348 (195.6)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">308 (124.3)</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">298 (121.9)</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">324 (125.0)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">356 (197.5)</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">
Pre- to postchange</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">111 (97.3)</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">91.9 (87.8)</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">32.1 (79.0)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">12.3 (80.3)</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Weight (kg) mean (SD)</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">54.1 (8.6)</td><td align="center" rowspan="1" colspan="1">47 </td><td align="center" rowspan="1" colspan="1">56.7 (9.6)</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">57.3 (9.1)</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">53.4 (7.8)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">54.2 (9.3)</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">57.3 (9.4)</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">57.2 (9.4)</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">53.3 (8.0)</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">
Pre- to postchange </td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.9 (3.0)</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.6 (2.3)</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">0.2 (2.1)</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.04 (1.8)</td><td align="center" rowspan="1" colspan="1">0.77</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of quality of life domains and change (mean, SD) from baseline to month 3 between intervention and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Treatment-naive patients</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="4" rowspan="1">Treatment-experienced patients</th><th align="center" rowspan="1" colspan="1">&#x02009;</th></tr><tr><th align="left" rowspan="2" colspan="1">Domain</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic> value</th></tr><tr><th align="left" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Intervention</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Control</th></tr></thead><tbody><tr><td colspan="11" align="center" rowspan="1">Physical well-being</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">12.6 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">13.8 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">0.044</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">14.3 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">13.9 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">0.478</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">16.5 &#x000b1; 4.0</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">15.8 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">0.414</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">16.8 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">16.3 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">0.319</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">2.55 &#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">2.38 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">0.817</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Psychological status</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">11.7 &#x000b1; 2.21</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">11.7 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">0.875</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">12.1 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">12.1 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">0.886</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">13.3 &#x000b1; 2.14</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">12.9 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">0.468</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">13.9 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">13.0 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">0.055</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 2.37</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">0.485</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">1.78 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">0.95 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">0.126</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Level of independence/work capacity</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">12.2 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">13.2 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">0.083</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">13.9 &#x000b1; 2.7</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">13.1 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">0.159</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">13.3 &#x000b1; 2.3</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">12.9 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">0.465</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">13.7 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">13.0 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">&#x02212;0.4 &#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">&#x02212;0.2 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">0.949</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Social relationships</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">13.2 &#x000b1; 2.3</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">13.5 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">0.477</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">13.3 &#x000b1; 3.1</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">13.4 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">0.864</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">15.0 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">14.4 &#x000b1; 2.7</td><td align="center" rowspan="1" colspan="1">0.353</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">14.9 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">14.3 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">0.172</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">0.7 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">0.114</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">1.7 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Environment</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">11.7 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">12.5 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">0.072</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">12.0 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">12.0 &#x000b1; 2.7</td><td align="center" rowspan="1" colspan="1">0.983</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">13.6 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">12.7 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">0.101</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">14.0 &#x000b1; 2.3</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">13.1 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">&#x02212;0.03 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td colspan="11" align="center" rowspan="1">Spiritual/religious/personal beliefs</td></tr><tr><td align="left" colspan="11" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">11.1 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">12.4 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">0.066</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">12.8 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">12.0 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">0.248</td></tr><tr><td align="left" rowspan="1" colspan="1">Month 3</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">15.5 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">14.6 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">0.297</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">16.2 &#x000b1; 2.9</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">15.1 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" rowspan="1" colspan="1">Change</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 2.9</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">0.021</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">3.3 &#x000b1; 4.5</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">0.836</td></tr></tbody></table></table-wrap></floats-group></article>